Clinical Trials Logo

Clinical Trial Summary

This is a clinical research study that is designed to test the safety of CYT997 when given to patients with multiple myeloma and to test if CYT997 has any activity against that cancer.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT00664378
Study type Interventional
Source Gilead Sciences
Contact
Status Terminated
Phase Phase 2
Start date January 2008
Completion date February 2011

See also
  Status Clinical Trial Phase
Recruiting NCT06050512 - Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma Phase 1/Phase 2
Completed NCT00932698 - Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma Phase 1
Terminated NCT03683277 - IPD in RRMM Characterized With Genomic Abnormalities of Adverse Prognostic Phase 2
Recruiting NCT04155749 - Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma Phase 1
Completed NCT03029234 - Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma Phase 3
Recruiting NCT05530421 - Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Phase 2
Not yet recruiting NCT03559764 - Study of BCMA CAR-T in Multiple Myeloma Early Phase 1
Completed NCT02144038 - Study of the Safety and Effectiveness of LGH447 and BYL719 in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT03710915 - A Study of HG146 Capsule in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 1
Terminated NCT02223598 - A Phase 1 Study Evaluating CB-5083 in Subjects With Lymphoid Hematological Malignancies Phase 1
Completed NCT03477643 - Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patients With Relapsed and Refractory Multiple Myeloma (RRMM)
Recruiting NCT03661554 - BCMA Nano Antibody CAR-T Cells for Patients With Refractory and Relapsed Multiple Myeloma Early Phase 1